Which startups will present at MedCity INVEST Precision Medicine Pitch Perfect?

by Bailey Amber
0 comment

Finish line ahead

The MedCity INVEST Precision Medicine healthcare conference on December 9-11 will draw healthcare and life science executives as we spotlight progress in the development of diagnostics, clinical trial innovation, AI in drug development, and reimbursement models for cell and gene therapy. But at the heart of the conference will be startups in health IT and life sciences.

Each startup will have four minutes to present their companies and six minutes to answer questions from judges.  The health IT track will be held on Wednesday, December 10 from 10am-11:30am ET and the life sciences track is scheduled for Friday December 11 from 2:30pm-4pm ET.

Click here to view the agenda. To register, click here.

Here’s a preview of who will be presenting in the Pitch Perfect contest:

Health IT Track

Backdrop Health, Inc. has created novel machine-learning and AI software that maximizes the value of electronic medical records, enabling a new level of precision predictive medicine. Backdrop’s solution radically extends the established concept of comorbidity (the occurrence of more than one condition in a patient at a time, such as obesity and diabetes). Given any body of medical records our software creates the backdrop for those records. A backdrop is a rich and comprehensive knowledge graph that captures the relationship of every clinical and demographic factor to every other factor. Querying the backdrop can bring massive benefits to clinical trials of new drugs, making it easier for pharmaceutical companies to bring new therapies to market, and to all aspects of personalized medicine, enabling health care providers to preemptively identify health issues and improve patient outcomes. Backdrop Health was launched in 2020 to commercialize this mature technology developed over four years at The University of Utah.

CEO: Jerry Rudisin

Headquarters: Salt Lake City, UT

Destroke is a digital health company developing a mobile app for automated clinical stroke detection.  This app uses speech, face, and motion recognition technologies to detect the signs of stroke, based on the validated NIH stroke scale, and can report these findings to patients, loved ones, telestroke providers, healthcare providers, and EMS.  This app is intended to be used by those at risk for stroke, such as patients who have had a stroke or those with cardiovascular risk factors, as well as healthcare providers who may not have expertise in stroke detection.

CEO: Evan Noch, MD

Headquarters: New York, NY

DrugViu’s digital platform makes medical research more inclusive and accessible by making it easy for diverse people living with autoimmune diseases to contribute their clinical grade data to research and participate in clinical research.

CEO: Kwaku Owusu

Headquarters: New York, NY

Parallel Profile is on a mission to save lives and billions in wasted healthcare spending by preventing adverse drug reactions.

CEO: Cathy Cather

Headquarters: Fort Lauderdale, FL


Siddarth Sridhar is a corporate development associate with Centene’s global M&A group.

Aron Starosta is VP of Commercialization and New Ventures, University City Science Center.

Life Sciences Track

Biomeme’s end-to-end mobile platform empowers you to take real-time PCR everywhere you need it, from sample collection to data management.

Biomeme started out by creating the first iPhone add-on capable of performing molecular diagnostics. Since our inception, we have used advanced biology and chemistry along with world-class hardware and software engineering to create elegant solutions to complex problems. Over the years our team has grown, and along the way Biomeme has built the leading mobile molecular diagnostics platform.

CEO: Max Perelman

Headquarters: Philadelphia, PA

EpiVario is a preclinical stage biotechnology company that is developing neuroepigenetic modulators to treat memory related psychiatric disorders. Our newly discovered epigenetic regulatory mechanism provides a target for treating memory-related neuropsychiatric disorders, since it plays a critical role in consolidating trauma-induced fear and stress responses, in addition to cue-induced craving that underlies various addiction disorders. Based on this paradigm-shifting finding, EpiVario is developing pharmacotherapeutics to treat anxiety and addiction disorders, including PTSD and alcohol use disorder.

CEO: Thomas Kim

Headquarters: Philadelphia, PA

Gregor Diagnostics is a molecular diagnostics company focused on developing a new screening test for prostate cancer. Prostate cancer screening has been a hotly debated topic over the last two decades because of the overdiagnosis and overtreatment caused by current screening methods. Gregor is developing a better solution that can limit these issues, while still saving men from this deadly disease.

CEO: Tobias Zutz

Headquarters: Madison, WI

SOLUtion is an early-stage life science company developing more patient friendly drug delivery systems for reconstitutable drugs. We specifically aim to improve the administration efficacy of life-saving injectable medication with our TwistJect auto-injector for people living with adrenal insufficiency including Addison’s Disease and Congenital Adrenal Hyperplasia.

CEO: Julia Anthony

Headquarters: Philadelphia, PA

Stingray Therapeutics is an immune oncology company leading the charge to bring the next generation of new immune oncology agents forward. Today, all our immune oncology therapeutics are in only one arm of the immune system – adaptive immunity. But the immune system has two major arms that synergistically work together, adaptive and innate immunity. Our program in innate immunity inhibits the direct negative regulator of the major pathway, adding innate immunity into the fight against cancer, and has the promise of making immune oncology therapy dramatically more effective.

CEO: Jonathan Northrup

Headquarters: Houston, TX

TrialSpark is a technology company that helps bring treatments to patients faster.

Today, clinical trials are the bottleneck to bringing life-saving treatments to patients. Trials are slow, inefficient, and expensive. We believe that we can use technology to accelerate the pace of clinical trials and bridge the gap between medical research and patients who need treatment.

Client Growth Director: Joe Zaccaria

Headquarters: New York, NY


Wayne Barz is Chief Investment Officer, Ben Franklin Technology Partners – Northeast PA.

Rena Rosenberg is a Partner with Robin Hood Ventures.

Picture: AdrianHillman, Getty Images

Related Posts